Clinical Trial

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-31
notable Trial sites expanded: 2 -> 6 locations 2026-07-31
Trial Details
NCT Number NCT07424833
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL)
Enrollment 180 participants
Start Date 2026-08
Primary Completion 2029-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30